Patents Assigned to ARIXA PHARMACEUTICALS, INC.
  • ORALLY ADMINISTERED COMBINATIONS OF BETA LACTAM ANTIBIOTICS AND AVIBACTAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS
    Publication number: 20230210863
    Abstract: Pharmaceutical compositions comprising a ?-lactam antibiotic and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions are disclosed. The pharmaceutical compositions can be formulated for oral administration and following oral administration provide a therapeutically effective amount of ?-lactam antibiotic and avibactam in the system circulation of a patient. The oral pharmaceutical compositions can methods can be used to treat infections caused by bacteria that produce ?-lactamase enzymes.
    Type: Application
    Filed: March 13, 2023
    Publication date: July 6, 2023
    Applicant: Arixa Pharmaceuticals, Inc.
    Inventors: Joaquim Trias, Carole Sable, Andrew Nicholls
  • BETA-LACTAMASE INHIBITORS AND USES THEREOF
    Publication number: 20230201218
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Application
    Filed: February 28, 2023
    Publication date: June 29, 2023
    Applicant: Arixa Pharmaceuticals, Inc.
    Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
  • Methods of synthesizing aztreonam derivatives
    Patent number: 11565999
    Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: January 31, 2023
    Assignee: Arixa Pharmaceuticals, Inc.
    Inventors: Eric M. Gordon, Matthew A. J. Duncton, John Freund
  • Derivatives of relebactam and uses thereof
    Patent number: 11180500
    Abstract: Derivatives of relebactam, therapeutic methods of using the derivatives of relebactam, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The derivatives of relebactam are suitable for oral administration.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: November 23, 2021
    Assignee: Arixa Pharmaceuticals, Inc.
    Inventors: Eric M. Gordon, Matthew A. J. Duncton, John Freund
  • ORALLY ADMINISTERED COMBINATIONS OF AMOXICILLIN AND AVIBACTAM DERIVATIVES FOR TREATING MYCOBACTERIAL INFECTIONS
    Publication number: 20210186983
    Abstract: Pharmaceutical compositions comprise amoxicillin and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions. The pharmaceutical compositions can be formulated for oral administration and following oral administration provide a therapeutically effective amount of amoxicillin and avibactam in the plasma of a patient. The oral pharmaceutical compositions and methods can be used to treat mycobacterial infections.
    Type: Application
    Filed: December 16, 2020
    Publication date: June 24, 2021
    Applicant: Arixa Pharmaceuticals, Inc.
    Inventor: JOAQUIM TRIAS
  • Crystalline form of an avibactam derivative
    Patent number: 11008321
    Abstract: A crystalline form of an avibactam derivative, pharmaceutical compositions thereof, and the use of the crystalline avibactam derivative for treating bacterial infections are provided.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: May 18, 2021
    Assignee: Arixa Pharmaceuticals, Inc.
    Inventor: Sami Karaborni
  • ORALLY ADMINISTERED COMBINATIONS OF BETA-LACTAM ANTIBIOTICS AND AVIBACTAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS
    Publication number: 20210060033
    Abstract: Pharmaceutical compositions comprising a ?-lactam antibiotic and an avibactam derivative and methods of treating bacterial infections using the pharmaceutical compositions are disclosed. The pharmaceutical compositions can be formulated for oral administration and following oral administration provide a therapeutically effective amount of ?-lactam antibiotic and avibactam in the system circulation of a patient. The oral pharmaceutical compositions can methods can be used to treat infections caused by bacteria that produce ?-lactamase enzymes.
    Type: Application
    Filed: August 27, 2020
    Publication date: March 4, 2021
    Applicant: ARIXA PHARMACEUTICALS, INC.
    Inventors: JOAQUIM TRIAS, CAROLE SABLE, ANDREW NICHOLLS
  • METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES
    Publication number: 20200339507
    Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.
    Type: Application
    Filed: April 6, 2020
    Publication date: October 29, 2020
    Applicant: ARIXA PHARMACEUTICALS, INC.
    Inventors: ERIC M. GORDON, MATTHEW A.J. DUNCTON, JOHN FREUND
  • Aztreonam derivatives and uses thereof
    Patent number: 10815228
    Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: October 27, 2020
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, Matthew A. J. Duncton, John Freund
  • CRYSTALLINE FORM OF AN AVIBACTAM DERIVATIVE
    Publication number: 20200291022
    Abstract: A crystalline form of an avibactam derivative, pharmaceutical compositions thereof, and the use of the crystalline avibactam derivative for treating bacterial infections are provided.
    Type: Application
    Filed: March 10, 2020
    Publication date: September 17, 2020
    Applicant: ARIXA PHARMACEUTICALS, INC.
    Inventor: Sami Karaborni
  • Beta-lactamase inhibitors and uses thereof
    Patent number: 10722521
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: July 28, 2020
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
  • DERIVATIVES OF RELEBACTAM AND USES THEREOF
    Publication number: 20200102307
    Abstract: Derivatives of relebactam, therapeutic methods of using the derivatives of relebactam, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The derivatives of relebactam are suitable for oral administration.
    Type: Application
    Filed: October 1, 2019
    Publication date: April 2, 2020
    Applicant: ARIXA PHARMACEUTICALS, INC.
    Inventors: ERIC M. GORDON, MATTHEW A.J. DUNCTON, JOHN FREUND
  • BETA-LACTAMASE INHIBITORS AND USES THEREOF
    Publication number: 20200046724
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the f-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Application
    Filed: October 16, 2019
    Publication date: February 13, 2020
    Applicant: ARIXA PHARMACEUTICALS, INC.
    Inventors: ERIC M. GORDON, JOHN FREUND, MARK A. GALLOP, MATTHEW ALEXANDER JAMES DUNCTON
  • Beta-lactamase inhibitors and uses thereof
    Patent number: 10500211
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: December 10, 2019
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
  • Aztreonam derivatives and uses thereof
    Patent number: 10280161
    Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with ?-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: May 7, 2019
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, Matthew A. J. Duncton, John Freund
  • Deuterated O-sulfated beta lactam hydroxamic acids and deuterated N-sulfated beta lactams
    Patent number: 10093666
    Abstract: Provided herein are deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: October 9, 2018
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventor: Eric M. Gordon
  • Beta-lactamase inhibitors and uses thereof
    Patent number: 10085999
    Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 2, 2018
    Assignee: ARIXA PHARMACEUTICALS, INC.
    Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton